AI assistant
ROCKET PHARMACEUTICALS, INC. — Director's Dealing 2025
Jul 18, 2025
33148_dirs_2025-07-18_3144a3ca-2ae8-41ce-9cb1-0bae159de1b0.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2025-06-18
Reporting Person: WONG RODERICK (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-06-18 | Common Stock | A | 30000 | — | Acquired | 30000 | Direct |
| 2025-06-18 | Common Stock | A | 17667 | — | Acquired | 47667 | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 18188457 | Indirect |
Footnotes
F1: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2026.
F2: Represents RSUs issued to the Reporting Person in lieu of director retainer fees of $50,000. The RSUs will vest in full on June 18, 2026.
F3: Represents shares held by certain investment funds managed by RTW Investments, LP (the "Adviser"). The Reporting Person serves as the Managing Partner and Chief Investment Officer of the Adviser and is a director of the Issuer and Chairman of the Issuer's Board of Directors.